FRESENIUS MEDICAL CARE - FINANCIAL FIGURES 2021
WHO WE ARE
Creating a future worth living. For our patients. Worldwide. Every day.
Fresenius Medical Care is the world's leading provider of products and services for individuals with kidney diseases of which around 3.8 million patients worldwide regularly undergo dialysis treatment. We care for more than 345,000 dialysis patients around the world. Their well-being always comes first. Since Fresenius Medical Care was founded in 1996, our aim has been to improve our patients’ quality of life by offering them high-quality products as well as innovative technologies and therapies.
With around 123,000 employees today, we intend to grow further and continue to use our experience, innovative research and value-based care approach to provide the best possible care for our patients. 2021 and the COVID-19 pandemic reminded us once again of the vulnerable patient population we serve and also showed the commitment of our employees to our patients.
patients
Around
dialysis treatments
in 2021
of our patients
would highly recommend
our services
dialysis centers
in around
50 countries
of dialysis treatments
in the U.S.
performed in-center
of dialysis treatments
in the U.S.
performed at home
production
sites
Products
in around
countries
We are the
clear market leader
in the production of
hemodialysis machines
More than
dialyzers produced
in 2021
improvements made to
our dialysis machines,
dialyzers, and solution products
environmental initiatives
reported at
our production sites
market share in
Continuous Renal
Replacement Therapy
Revenue
Revenue growth at constant currency achieved
NORTH AMERICA
EUROPE, MIDDLE EAST AND AFRICA
ASIA-PACIFIC
LATIN AMERICA
HEALTH CARE SERVICES
HEALTH CARE PRODUCTS
Operating
Income
Earnings development affected by COVID-19
1At constant currency
22021: costs related to the FME25 program; 2020: impairment of goodwill and trade names in the Latin America segment
Net
Income
Results in line with guidance despite stronger-than-anticipated headwinds
1At constant currency
2Net income attributable to shareholders of Fresenius Medical Care AG & Co. KGaA
32021: costs related to the FME25 program; 2020: impairment of goodwill and trade names in the Latin America segment
Dividend
25th consecutive dividend increase to be proposed
1Proposal to be approved by the Annual General Meeting on May 12, 2022